PubMed Health⌕ Search

Biomedical subjects

F Rousselot

Publications and source records attributed to F Rousselot.

7 recordsLinked to original sources
PubMed2004

[Arguments for deciding to change treatment in benign prostatic hyperplasia].

Insufficient efficacy above all, but also the appearance of side effects or the occurrence of complications may motivate a change in the treatment of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (HBP). In terms of efficacy, surgery remains superior to all medical treatments including alphablockers which are the most active. 5-alpha-reductase inhibitors have a slow efficacy which is all the more marked when the prostatic volume is large. Phytotherapy has a slight activity which is higher than that of placebo. Drug combinations are currently being studied and, although a benefit has been shown in certain publications, their clinical efficacy remains to be specified. They may become an alternative in case of failure of single-agent therapy to prevent or delay surgery. The incidence of side effects is low and varies with the treatment used and within a same therapeutic class. With alphablockers for instance, orthostatic hypotension, which is the main side effect, varies from 1% to 8% approximately depending on the study and molecule. The side effects of 5-alpha-reductase inhibitors are mainly sexual disorders, observed in 1 to 4% of cases approximately. Hence, the occurrence of a drug side effect causing treatment discontinuation should incite a change of molecule, even within the same class for alphablockers. On the other hand, if complications of HBP occur, it is then necessary to resort to surgery.

Humans↗
PubMed1996

[Renal endometriosis. Report of a case].

In the light of a personal case and a review of the literature, the authors recall the specific features of renal endometriosis. This rare lesion, with a favourable prognosis, is difficult to diagnose and is rarely diagnosed preoperatively. Medical treatment by LHRH agonists is discussed and has been used exceptionally.

Adult↗
PubMed1982

[Trial of the therapeutic efficacy of cis-diamino-dichloro-platinum by local instillations on bladder tumours recurring at the original site (author's transl)].

Cis-diamino-dichloro-platinum (DDP) was administered to fourteen patients with a carcinoma of the bladder recurring at the original site and all analysed from a histological standpoint. All the patients had received multiple therapy previously. The tumours treated included the following: eight superficial tumours not infiltrating the chorion, four tumours involving the chorion, one tumour involving the internal muscle layer and one tumour in situ. The age range of the patients was 52 to 81 years with a mean of 69.6 years. Administration was by intra-vesical instillation of 100 mg of DDP each week for the first six weeks, then every two weeks for the next two months and finally once a month. Results were assessed on the basis of endoscopic appearance, cytology and, where applicable, biopsy. Amongst the superficial tumours not infiltrating the chorion, results were as follows: three complete remissions of respective durations of 8 months, 5 months and more than 2 months; three partial remissions of respective durations of 7 months, 6 months and 5 months; and finally two minor remissions of 5 months and 2 months. There were no failures. Amongst tumours invading the chorion, results were as follows: one complete response lasting for 10 months; 2 minor remissions of short duration: 2 months and 2 months; and one failure. Treatment of the one tumour invading the internal layer of muscle was a failure. Finally, the tumour in situ was difficult to evaluate but showed a complete response lasting for 2 months.

Adult↗
PubMed1980

[Evaluation of the efficacy of cis-diamino-dichloro-platinum as monochemotherapy in the treatment of advanced malignant tumours of the bladder (author's transl)].

The authors report the results of a trial of the treatment of recurrences of advanced carcinomas of the bladder using Cis-Diamino-Dichloro-Platinum administered by continuous IV infusion over a period of 24 hours at a dose of 100 mg/m2, under cover of hyperhydration and anti-haematizing drugs. The trial involved 10 patients who has had the following initial treatment : - excision for 8 of them (2 total cystectomies for T4, one total cystectomy for T3B, 2 total cystectomies for T3A and 3 partial cystectomy for T1); - preoperative cobalt therapy for 7 of them (2 flashes of 7.5 gray) - postoperative chemotherapy (VM26 and 5FU) for 5 patients. The targets evaluated were : 7 remaining pelvic tumours or recurrences, 3 lung metastases, two cases of venous compression with oedema of the lower limbs, 3 node metastases, 3 bone and 1 sciatic metastases. Results : - 1 complete remission with disappearance for 10 months in the same patient of pulmonary metastases, venous compression and an inguinal node; - 3 partial remissions for 2 to 9 months; - 2 minor remissions of 3 to 5 months; - 3 stabilizations and 1 progression. It is interesting to note the greater efficacy on distant metastases (2/3 complete disappearances of lung metastases, 2/2 disappearances of oedema of the lower limbs) than on pelvic tumours (4/7 regressions). In total, 4 objective responses out of 10 occurring between the 2nd and 6th week after the first course. The authors announce a valuable synergism of DDP with cyclophosphamide and adriamycin.

Aged↗